Guidant Corp.
Boston Scientific looks to quash kickbacks lawsuit
Magistrate orders feds to cough up Medicare docs in Guidant lawsuit
Boston Scientific (NYSE:BSX) won a bid to force the federal government to release Medicare documents covering reimbursement for implantable cardiac rhythm management devices in a whistleblower lawsuit filed against its embattled Guidant subsidiary.
Did Boston Scientific overpay for Guidant? | Wall Street Beat
Medical device giant Boston Scientific (NYSE:BSX) has notched billions in goodwill write-offs related to its 2006 acquisition of Guidant Corp., a signal that the $28 billion purchase price was too high, the Wall Street Journal reported.
Boston Scientific’s CEO defends the troubled Guidant buyout | Wall Street Beat
Boston Scientific’s (NYSE:BSX) interim CEO Hank Kucheman still believes in the company’s ill-fated acquisition of Guidant Corp., a deal worth $26 billion that was followed by recalls, lawsuits and criminal charges.
Medical device advisories: moving the needle
In 2005, a flurry of medical device recalls shook the implantable cardiac defibrillator market. The first of these recalls occurred after the former Guidant Corporation (just purchased by Boston Scientific) was forced to admit that a header malfunction of one of their Prism II ICDs had short-circuited and failed to deliver appropriate resuscitating shocks to several patients.
Former Orthofix VP convicted in kickbacks scheme | Legal News
Former Guidant sales rep gets green light to pursue lawsuit | Legal News
MassDevice.com +3 | The top 3 med-tech stories for April 2, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Hauser calls out the FDA, Guidant on recalled devices | MassDevice.com On Call
MASSDEVICE ON CALL — It was the death of a 21-year-old patient whose implanted cardiac defibrillator failed to shock his heart back to normal rhythm that started Dr. Robert Hauser on the path to becoming a vocal advocate for change at the FDA.
Joshua Oukrop, just a teenager when he received a Guidant ICD for a congenital heart condition, died when the implant shorted out instead of providing the necessary shock to his heart.
MassDevice.com +3 | The top 3 med-tech stories for March 15, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.